Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy? Journal Article

Local Library Link: Find It @ Loyola

Authors: Patel, DJ; Lutfi, W; Sweigert, P; Eguia, E; Abood, G; Knab, L; Kuo, PC; Baker, MS
Article Title: Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy?
Abstract: BACKGROUND: Prior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered. METHODS: We queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy. RESULTS: 298 patients met inclusion criteria: 38 received no treatment; 60 received systemic therapy alone; 84 received surgical resection alone; 116 underwent resection followed by adjuvant systemic therapy. On univariate analysis, resection was associated with a survival benefit compared to no treatment and systemic therapy alone (3-year overall survival: 57% vs. 26%, p?0.001). On Cox analysis, use of adjuvant therapy was associated with a survival benefit compared to resection alone (HR 0.54, 95% CI: 0.33-0.89). CONCLUSIONS: Adjuvant therapy is associated with a significant survival benefit in patients with resectable acinar cell carcinoma.
Journal Title: American Journal of Surgery
ISSN: 1879-1883; 0002-9610
Publisher: Elsevier Inc  
Date Published: 2019